Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Pablo_J._Cagnoni
|
| gptkbp:focus |
cellular therapies
red blood cell therapeutics |
| gptkbp:foundedYear |
2013
|
| gptkbp:founder |
gptkb:Flagship_Pioneering
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:RUBY-Red_Platform
|
| gptkbp:parentCompany |
gptkb:Flagship_Pioneering
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
oncology
rare diseases autoimmune diseases |
| gptkbp:status |
filed for bankruptcy in 2023
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:RUBY
|
| gptkbp:website |
https://www.rubiustx.com/
|
| gptkbp:bfsParent |
gptkb:Arch_Venture_Partners
gptkb:Alexandria_Venture_Investments gptkb:Flagship_Pioneering gptkb:Third_Rock_Ventures gptkb:Bob_Langer |
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rubius Therapeutics
|